Which pill stops the itch? new study pits bilastine against levocetirizine for hives
NCT ID NCT07365683
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different antihistamine treatments in 60 adults with chronic hives (itchy welts that keep coming back). One group took a higher dose of bilastine, the other took a mix of bilastine and levocetirizine. The goal was to see which approach better reduces itching and welts over 6 weeks. The results help doctors choose the best treatment for symptom control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with diagnosis of CSU as per operational definitions. * Patients already taking Bilastine 20 mg and still getting new lesions. * UAS7 score \>3 * Age range of 18-70 years * Both male and female patients Exclusion Criteria: * • women Patients who have already received treatment of CSU other than Bilastine. * Patients taking oral or topical corticosteroids * Pregnant or lactating * Patients with hereditary angioedema, atopic dermatitis, systemic immune disorders, collagen vascular diseases, immunocompromised status, Chronic liver or kidney failures
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic spontaneous urticaria are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
combined military hospital ,Okara
Okāra, Punjab Province, 56300, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.